| Literature DB >> 31892264 |
Kuo-Yuan Huang1, Shang-Chi Lee2, Wen-Lung Liu1, Jung-Der Wang3.
Abstract
BACKGROUND: There are still debates on the long-term outcome of treating pathological thoracolumbar fractures, including osteoporosis and oncologic problems, using vertebroplasty.Entities:
Keywords: National Health Insurance Research Database; PMMA cement; pathological fracture; thoracolumbar fracture; vertebroplasty
Year: 2019 PMID: 31892264 PMCID: PMC7019827 DOI: 10.3390/jcm9010078
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Figure 1Schematic diagram of the selection of study subjects.
Demographic and clinical characteristics of included patients stratified by conservative treatment, vertebroplasty and conventional open surgery.
| Treatment | Conservative Treatment ( | Vertebroplasty ( | Conventional Open Surgery ( |
|---|---|---|---|
| Gender ** (%Males) | 44.8 | 25.1 | 43.4 |
| Age ** < 59 (%) | 40.1 | 16.8 | 45.1 |
| 60–64 (%) | 7.0 | 7.5 | 7.5 |
| 65–69 (%) | 8.6 | 10.4 | 10.2 |
| 70–74 (%) | 12.1 | 15.9 | 12.6 |
| 75–79 (%) | 12.8 | 20.9 | 12.4 |
| >79 (%) | 19.4 | 28.4 | 12.3 |
| No. of deceased ** (%) | 26.2 | 19.2 | 17.4 |
| Comorbidity: | |||
| All cancer (%) | 2.6 | 2.5 | 1.6 |
| Lung cancer (%) | 0.5 | 0.5 | 0.5 |
| Liver cancer (%) | 0.4 | 0.5 | 0.5 |
| Colon cancer (%) | 0.3 | 0.4 | 0.4 |
| Kidney failure (%) | 1.7 | 1.7 | 1.2 |
| Stroke * (%) | 4.6 | 3.5 | 2.9 |
| Diabetes mellitus (%) | 4.0 | 3.3 | 5.0 |
| Autoimmunity disease (%) | 0.5 | 0.8 | 0.5 |
| COPD ** (%) | 2.8 | 0.9 | 1.8 |
| Hip fracture (%) | 2.5 | 2.0 | 1.6 |
| Complication | |||
| Pulmonary embolism (%) | 0.7 | 0.4 | ≦0.3 |
| Vertebral osteomyelitis or infections (%) | 0.9 | 1.0 | 1.0 |
| Adjacent fracture, refracture or other vertebral fracture (%) | <0.05 | <0.25 | <0.25 |
| Follow-up time ** (years) | 4.8 ± 3.2 | 3.2 ± 2.5 | 4.7 ± 3.1 |
*: p < 0.05; **: p < 0.0001; COPD: chronic obstructive pulmonary disease.
Figure 2Kaplan–Meier survival curves of different treatments for patients whose ages were more than 75 years old. The y-axis indicates the survival rate, and the x-axis represents the time after diagnosis (or operation), while the frequencies on the bottom show the number of patients in each group that still survived up to that time point. Log rank test analysis showed a significant difference (p = 0.0002) between conservative treatment and vertebroplasty, while there was no significant difference (p = 0.64) between vertebroplasty and conventional open surgery.
Hazard ratio (HR), adjusted HR (aHR), and 95% confidence interval (CI) of prognostic factors estimated from Cox proportional hazard model.
| Variables | Simple Cox Model | Multiple Cox Model | ||
|---|---|---|---|---|
| HR | 95% CI | aHR | 95% CI | |
| Gender (M/F) | 1.02 | (0.93–1.11) | 1.45 | (1.32–1.58) |
| Age < 59 | 1 | 1 | ||
| 60–64 | 2.11 | (1.63–2.74) | 2.23 | (1.71–2.89) |
| 65–69 | 3.02 | (2.44–3.73) | 3.24 | (2.61–4.02) |
| 70–74 | 4.81 | (4.04–5.73) | 5.06 | (4.23–6.06) |
| 75–79 | 7.57 | (6.44–8.90) | 8.10 | (6.85–9.58) |
| >79 | 13.71 | (11.80–15.94) | 13.87 | (11.86–16.21) |
| Conservative treatment | 1 | 1 | ||
| Vertebroplasty | 1.07 | (0.94–1.22) | 0.87 | (0.77–0.99) |
| Conventional open surgery | 0.68 | (0.59–0.79) | 0.80 | (0.70–0.93) |
| Comorbidity | ||||
| All cancer | 4.43 | (3.73–5.27) | 2.20 | (1.72–2.82) |
| Lung cancer | 8.40 | (6.09–11.59) | 2.80 | (1.88–4.16) |
| Liver cancer | 7.33 | (5.11–10.52) | 2.70 | (1.77–4.11) |
| Colon cancer | 2.63 | (1.58–4.37) | 0.55 | (0.31–0.95) |
| Kidney failure | 3.50 | (2.79–4.40) | 1.96 | (1.55–2.46) |
| Stroke | 2.16 | (1.84–2.53) | 1.17 | (1.00–1.38) |
| Diabetes mellitus | 1.55 | (1.30–1.85) | 1.11 | (0.93–1.33) |
| Autoimmunity disease | 0.91 | (0.52–1.61) | 0.73 | (0.41–1.29) |
| COPD | 3.85 | (3.25–4.57) | 1.61 | (1.35–1.92) |
| Hip fracture | 2.59 | (2.13–3.15) | 1.43 | (1.17–1.75) |
| Complication | ||||
| Pulmonary embolism | 3.44 | (2.37–4.99) | 1.81 | (1.24–2.63) |
| Vertebral osteomyelitis or infections | 1.98 | (1.41–2.78) | 1.73 | (1.23–2.44) |
COPD: chronic obstructive pulmonary disease.